The drug, administered through an IV, is said to work swiftly, with patients feeling relief within 48 hours, according to the New York Times.
United States authorities on Tuesday approved the first medication designed specifically to treat post-partum depression, an illness that affects about one in nine new American mothers.
Postpartum depression is much more severe and longer-lasting than the "baby blues" many new mothers experience for about a week after giving birth.
You'll get the latest updates on this topic in your browser notifications.
The drug's trade name is Zulresso.
Zulresso might cost up to $34,000 per patient, excluding the costs associated with several days stay in a medical center. The Times said that insurers are now assessing the drug.
"Postpartum depression is a serious condition that, when severe, can be life-threatening", said Dr. Tiffany Farchione, the F.D.A.'s acting director of the Division of Psychiatry Products.
Until now, the only treatment options for people with postpartum depression included counseling or talk therapy, and antidepressant medications that aren't specifically FDA-approved for helping new mothers with postpartum depression, according to the National Institute of Mental Health. In trials, women said they felt marked improvement within 24 hours.
Sage Therapeutics is also working on a pill form of the drug that appears to be working just as well, the Times reported, and the company expects to have it ready in the next couple of years.